Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
-0.41%
)
US TECH 100
26,233.20
(
0.68%
)
Dow Jones
49,310.32
(
-0.36%
)
Brent Oil
101.98
(
0.77%
)
Bitcoin
77,462.54
(
-1.04%
)
News Focus
News Focus
Post# of 257442
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122884
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: randychub post# 233845

Friday, 07/24/2020 1:24:25 PM

Friday, July 24, 2020 1:24:25 PM

Post# of 257442
Evaluating ABUS requires an assessment of the HBV program, which I’ve posted about from time to time—see, for instance, #msg-154612542 and the thread it replies to. (#msg-151513575 has info on a now-defunct ABUS HBV compound.)

2% seems a little low for the presumed LNP royalty, assuming that ABUS continues to prevail in continuing litigation with MRNA.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today